Conducting new experimental studies on E-cadherin-targeted therapies in lung diseases due to respiratory barrier dysfunction such as COPD, idiopathic pulmonary fibrosis and ARDS will support this issue. The gene discussed is CDH1; the disease is pulmonary fibrosis.